Generating monoclonal antibodies from single B cells is a valuable tool for characterizing the specificity and functional properties of humoral responses. We and others developed protocols that have facilitated major advances in our understanding of B cell development, tolerance, and effector responses to HIV and influenza. Here, we demonstrate various refinements and dramatically reduce the time required to produce recombinant antibodies. Further, we present new methods for cloning and isolating antibodies from cells with lower immunoglobulin mRNA levels that may be resistant to traditional techniques. Together, these refinements significantly increase single-cell antibody expression efficiency and are easily integrated into established and novel pipelines.
responses by production of monoclonal antibodies from single cells has enabled rapid advances in B cell biology due to the high throughput and efficiency of these methods [1] [2] [3] . These include the isolation of large numbers of broadly neutralizing antibodies against diverse pathogens like HIV and influenza, which are revolutionizing vaccine and therapeutic design. Single cells from a population of interest are isolated using flow cytometry then immunoglobulin genes from each cell are cloned into a vector for protein expression. The resulting antibodies are used for downstream assays to study their specificity, function, and repertoire characteristics.
A popular use for this involves screening panels of monoclonal antibodies, allowing a clonal assessment of the specificities present in a population of interest. Antibodies derived from plasmablasts, the temporary effector cells that peak 7 days after an immune response, present an opportunity to study acute infection and vaccination 4, 5 . Memory B cells give access to affinity-matured antibodies, especially those formed during chronic or repeated infections 6, 7 . An advantage of this method over traditional serum or hybridoma methods is that rare single cells with desirable antibodies can be isolated. Characterization of individual monoclonal antibodies yields data on specificity, binding conformation, reactivity breadth and potency, and protective capacity. Studies using these methods have shed light on potential targets for universal vaccine development and provide benchmarks for evaluating future therapeutics.
Here, we show several refinements for single-cell cloning and antibody expression that eliminate bottlenecks by replacing various single-sample manipulations with highthroughput alternatives. For large-scale projects, these changes are easily implemented and noticeably increase the pace at which antibodies can be generated. Further, our methods enable high-throughput isolation and characterization of antibodies from cells with relatively low immunoglobulin expression levels such as naïve or memory B cells. Limitations that are inherent to generating antibodies from single cells remain, including cell fragility (plasmablasts cannot be frozen and thawed) and the time-consuming nature of sorting cells and transfecting individual antibodies. Additionally, the lack of PCR error correcting mechanisms necessitate redundancy measures and the occasional redo. Instructions and primers for creating both fully human and chimeric (murine variable region and human constant region) antibodies are included.
Methods
This section describes the steps that are substantially different from our previously published protocol 3 . A complete protocol, which includes other modifications and quality-of-life changes, is included as supplementary material. Table 1 compares the bench time required for each step for our old protocol and this new protocol.
We applied this procedure to human plasmablasts isolated seven days after seasonal influenza vaccination and pneumococcal vaccination. We validated the cloning efficiency of the new protocol ( Figure 1a ) and confirmed the production of vaccine-specific antibodies by ELISA (Figures 1b, 1c ).
Peripheral blood samples were collected in accordance with the University of Chicago Institutional Review Board (#09-043-A) and informed consent was obtained from all subjects.
cDNA preparation
To prepare template cDNA from lysed cells, a non-specific cDNA synthesis kit is used rather than immunoglobulin-specific primers. With specific primers, for each sample plate only one of the light chain genes (lambda or kappa) can be reverse transcribed, and antibodies that use the other gene are lost. With non-specific primers, both lambda and kappa chain DNA can be recovered from the same plate. Important: use RNase-free precautions.
Direct cDNA synthesis from sorted and lysed cells
This is efficient for most cell types, especially plasmablasts. Non-plasmablast human cells may experience slightly diminished PCR efficiency.
Note: Sort cells into 10 µl/well of catch buffer (for ten half-plates: 5 ml RNase-free water, 50 µl 1M Tris pH 8.0, 125 µl RNasin; make fresh each time)
1.
Create the master mix. 
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Note: Do not sort cells into catch buffer. Instead, use 5 µl/well of TCL buffer and 1% beta-mercaptoethanol (vol/vol). Plates can be flash-frozen on dry ice and stored at −80°C.
1.
Warm RNase-free SPRI beads to room temperature.
2.
Add 10 µl nuclease-free water to each sample, then add 33 µl SPRI beads to each sample. Cover plate to prevent contamination and incubate at room temperature for 10 min.
3.
Place the plate on top of the magnetic plate and incubate, covered, at room temperature for 5 minutes.
4.
Wash the plate 3x with 75 µl 80% EtOH, incubating 30 sec each cycle. Upon final aspiration, air dry for 8 min and remove from the magnetic plate.
5.
Begin cDNA synthesis by resuspending beads in 10 µl/well reverse transcription mix #1, and thermocycle. reaction to generate DNA for insertion into expression vectors. We designed sequencespecific primers that each contain an overhanging region that overlaps with the proper expression vector. To join the insert with the vector, we use Gibson assembly, a rapid procedure for assembling DNA fragments with overlapping ends 9 (Figure 3 ). Overall, this process is much quicker than the traditional digest-ligation method and slightly more reliable, reducing the number of sequences that must be redone (data not shown). 
Materials

5.
Run on a 1.2% agarose gel (100V for 5 min, then 75V for 75 min) and cut bands with the digested vectors from the gel for extraction.
6.
Purify by following the protocol outlined in the GeneJET Gel Extraction Kit with one exception: elute the final product in 40 µl EB.
Perform overlap PCR with Gibson assembly primers Important: to avoid contamination, avoid contact with the interior of Eppendorf tubes and limit airflow over open racks. Wipe pipettes and surfaces with DNA off before use.
1.
Create a master mix for each combination of 5' and 3' primers (for details on choosing primers, refer to the Supplementary Methods) . The template is the unpurified product of the 1st PCR step. Include a template-less negative control for each master mix of primers to ensure there is no contamination. The above PCR details are optimized for human primers; see the supplementary methods for mouse cloning PCR instructions.
2.
Run 2 µl PCR product directly on a 1% agarose gel to confirm a successful reaction and to check for contamination in the negative control wells.
1.
Reaction setup (it is not necessary to purify the cloning PCR products: Gibson assembly and bacterial transformation are equally effective when using unpurified PCR products) 
2.
Incubate the reaction in a thermocycler at 50°C for 1 hr. The assembled product can be stored at −20°C before transformation. Schematic for cloning antibody genes into expression vectors. PCR with gene-specific overhang primers frames the antibody gene on both sides with approximately 20-25 bp of overlap with the expression vector. Gibson assembly is then used to join the two fragments. Comparison of the bench time required to perform the steps in the protocol.
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